weixin.sogou.com·· 11 hours agoPickScore95
HORIZON-Breast06 Phase III Head-to-Head: SHR-A1811 Extends Median PFS From 6.8 to 16.4 Months in HER2-Low Advanced Breast Cancer
In brief
The phase III head-to-head HORIZON-Breast06 study showed that rezatruzumab (SHR-A1811) extended median PFS in the overall HER2-low advanced breast cancer population from 6.8 months in the control group to 16.4 months (HR=0.27, P<0.001).
Why it matters
Head-to-head phase III data report PFS, HR and ORR across the overall, pre-chemotherapy and HR-negative populations, plus ILD incidence.
Source: weixin.sogou.com · weixin.sogou.com